Many oncogenes such as Ras induce senescence-like phenotypes termed oncogene-induced senescence (OIS). It is well established that OIS is a barrier of tumorigenesis, and OIS has to be suppressed for cells to be transformed by oncogenes. However, how OIS is suppressed during cell transformation remains unclear. In addition to suppressing OIS, oncogenes have to reprogram cellular metabolism to glycolysis to facilitate tumorigenesis and cancer progression. One of the major mechanism by which Ras induce metabolic reprograming is through upregulation of hypoxia-inducible factor 1 (HIF1). It is also unclear how Ras upregulates HIF1. We recently found that the E3 ubiquitin ligase subunit WSB1 plays a role in suppressing OIS and promoting metabolic reprogramming downstream of Ras. WSB1 is overexpressed in several human cancers including breast cancer, pancreatic cancer and melanoma. We show that WSB1 is upregulated by oncogenic Ras and Myc, and expression of WSB1 in primary MEFs expressing oncogenic Ras contributes to the suppression of OIS, leading to abnormal proliferation and cell transformation. Conversely, WSB1 downregulation promotes OIS. Mechanistically, we found that WSB1 negatively regulates ATM, which is important for inducing OIS. In addition, we found that WSB1 upregulates HIF1? and promotes metabolic phenotypes consistent with increased glycolysis. We hypothesize that WSB1 is a key player in early oncogenic events to i) suppress the DNA damage response and OIS through ATM degradation and ii) promote metabolic reprogramming through the HIF1 pathway. To test this hypothesis, we propose the following specific aims: 1. Study the regulation of ATM, the DNA damage response and OIS by WSB1;2. Study the regulation of HIF1? by WSB1;3. Generate WSB1 knockout mice to study the role of WSB1 in cancer development and progression. These studies will elucidate both a new factor that contributes to Ras induced tumorigenesis and a novel mechanism by which OIS is suppressed and metabolic reprogramming is induced. Because oncogenic Ras plays an important role in tumorigenesis in a variety of human cancers, our study will have significant impact on current understanding of the cause and progression of human cancer.

Public Health Relevance

Ras is abnormally activated in many human cancers and is a driver for tumorigenesis. How Ras induces tumors remains unclear. We have found that WSB1 is a downstream effector of WSB1 and based on our initial studies, we hypothesize that WSB1 contributes to tumorigenesis through its effect on cell cycle progression and cellular energy metabolism. We will study how the Ras-WSB1 signaling pathway can overcome barriers for tumorigenesis and remodel cellular energy metabolism. We will also use animal models to study how WSB1 contributes to tumorigenesis in organisms. Understanding of this signaling pathway will have profound and wide application in human cancers with Ras mutations.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Pelroy, Richard
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Wu, Chenming; Luo, Kuntian; Zhao, Fei et al. (2018) USP20 positively regulates tumorigenesis and chemoresistance through ?-catenin stabilization. Cell Death Differ 25:1855-1869
Li, Lei; Liu, Tongzheng; Li, Yunhui et al. (2018) The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization. Oncogene 37:2422-2431
Nowsheen, Somaira; Aziz, Khaled; Luo, Kuntian et al. (2018) ZNF506-dependent positive feedback loop regulates H2AX signaling after DNA damage. Nat Commun 9:2736
Liu, Tongzheng; Yu, Jia; Deng, Min et al. (2017) CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. Nat Commun 8:13923
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2017) Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. Breast Cancer Res 19:130
Kim, Jung Jin; Lee, Seung Baek; Yi, Sang-Yeop et al. (2017) WSB1 overcomes oncogene-induced senescence by targeting ATM for degradation. Cell Res 27:274-293
Luo, Kuntian; Li, Yunhui; Yin, Yujiao et al. (2017) USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling. EMBO J 36:1434-1446
Deng, Min; Yang, Xu; Qin, Bo et al. (2016) Deubiquitination and Activation of AMPK by USP10. Mol Cell 61:614-624
Liu, Tongzheng; Fang, Yuan; Zhang, Haoxing et al. (2016) HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. Cancer Res 76:572-81
Luo, Kuntian; Li, Lei; Li, Yunhui et al. (2016) A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination. Genes Dev 30:2581-2595

Showing the most recent 10 out of 18 publications